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Thiomarinols (1-6) are an unusual group of hybrid antibiotics produced by the marine bacterium Pseudoalteromonas sp. SANK73390 (Figure 1 ). [1] They combine close analogues of the clinically important agent, mupirocin (a mixture of pseudomonic acids, PA A-C, 7-9) [2] with the pyrrothine subunit of the holomycin class of antibiotics. Both thiomarinols and mupirocin display potent activity against MRSA (methicillin-resistant Staphylococcus aureus), [3] and belong to the trans-AT class of modular polyketide-derived antibiotics. [4] The mup biosynthetic gene cluster was one of the first of this class to be discovered, [5] but there are now more than 20 at least partially characterised, with many others known from genomic sequences. [4] Thiomarinols can be regarded as comprising three main elements: a highly functionalised polyketide-derived acid, which is esterified by 8-hydroxyoctanoic acid, which itself forms an amide with the bicyclic amino acid-derived pyrrothine. The major components TM-A 1 and PA-A 7 differ in the lack of a 10,11-epoxide, the presence of a 4-hydroxyl, a C8 rather than a C9 fatty acid, and the pyrrothine in TM-A. [6] The 6,7-dihydroxytetrahydropyran (THP) ring is necessary for the biological activity of mupirocin and thiomarinol, so elucidation of the biosynthetic mechanisms for ring formation and further modifications to the 6,7-diol is important. Mutational analysis of mupirocin biosynthesis showed somewhat counter-intuitively: (a) that the 8-hydroxyl of PA-B 8 has to be lost not gained, with feeding experiments confirming that PA-B is an intermediate in the biosynthesis of PA-A 7 [7] and (b) that PA-C 9 is the product of a parallel pathway that branches from the main pathway (to PA-A) following failure to undergo epoxidation of the 10,11-double bond. [8] Analyses of mutant strains [9] indicate that putative biosynthetic precursor 12 (Scheme 1) is cyclised and esterified to give PA-B with the tetrahydropyran ring. In addition, identification of minor metabolites with C5 and C7 fatty acid side-chains are in accord with elaboration of the 9-hydroxynonanoic acid moiety occurring by initial addition of 3-hydroxypropionate followed by 3 successive MmpB-mediated chain elongations. [7b] Figure 1. Selected thiomarinols and pseudomonic acids.
New insights into the mechanism of PA-B to PA-A conversion -MupP acts as a dehydratase.
Conversion of PA-B 8 to PA-A 7 (replacing 8-OH with 8-H) has been shown to require MupU (CoA-ligase) and MacpE (ACP), MupO (P450), MupV (see below), MupC (enoate reductase) and MupF (ketoreductase) via the isolated intermediates mupirocin C1 14 and mupirocin F1 15, as shown in Scheme 1. Deletion of any of mupO, mupU, mupV or macpE all gave PA-B 8 as the major product along with the macrolactone 10. [8] The first step in the conversion of PA-B 8 to PA-A 7 is MupU catalysed ligation of PA-B to MacpE (Scheme 1) followed by oxidation (MupO). However, no metabolite corresponding to the putative hydroxyketone product 13 of MupO had been detected. Isolation and identification of these epoxide-containing metabolites is challenging as they are prone to rearrangements but are key to elucidating the remaining biosynthetic steps from PA-B to PA-A. Indeed PA-A itself is limited to mainly topical applications due to its instability in serum. [3] Our first goal was to establish the proposed 7-hydroxy-6-ketone 13 as a biosynthetic intermediate to PA-A. Analysis of a mupP strain revealed an unstable metabolite with MW 514 and detailed 1D and 2D NMR confirmed the structure of this key intermediate which is now named mupirocin P (13) .
Scheme 1. MupP acts as a dehydratase in mupirocin biosynthesis
We have shown previously that the OR domain of MmpE is responsible for epoxidation. [8] Thus a double mutant, mmpEOR/mupP strain was constructed. Gratifyingly, this produces the less labile desepoxy-mupirocin P 16 as the main metabolite along with a small amount of desepoxy-PA-B 17 ( Figure 2 ). MupP had not been previously assigned a function. Bioinformatic analysis indicates that it belongs to the glyoxalase/bleomycin resistance protein/dioxygenase superfamily but appears to act here overall as a dehydratase to give enol-ketone 14 (Scheme 1). Previous mutasynthesis studies on mupirocin biosynthesis [8] showed that PA-B 8, mupirocin C1 14 and mupirocin F1 15 were all efficiently (15-50%) converted to PA-A 7 by mutant strains of P. fluorescens blocked in earlier parts of the pathway, thus confirming their role as intermediates in mupirocin biosynthesis. To investigate if the 7-hydroxy-6-ketone is also a true intermediate on the pathway, desepoxy-mupirocin P 16, isolated from the mmpEOR/mupP strain, was fed to cultures of the mmpEORmupW strain and LC-MS showed a peak with the same retention time as desepoxy-mupirocin P but with MW 484. The metabolite was isolated and NMR revealed that PA-C had been produced confirming that desepoxy-mupirocin P is indeed an intermediate in PA-C 9 biosynthesis (Scheme 2). Reanalysis of the MupV amino acid sequence, which had previously been identified as a putative oxidoreductase, revealed a second domain with ca. 30% sequence identity to many Pseudomonas hydrolases. These contain a GXCXG consensus sequence where cysteine replaces the more common nucleophilic serine and includes an amino transferase involved in shuffling intermediates between thiolation domains in the syringomycin biosynthetic pathway in Pseudomonas syringae. [10] Thus MupV may act as a thioesterase or perhaps in some related ACP transfer capacity. Previously deletion of mupV had provided few clues as this yielded PA-B 8 as the major product. [9c] However, in this study, feeding desepoxy-mupirocin P 16 to the mupV strain gave PA-C in accord with a Mup V activity being required before MupP leading to mupirocin P 13 (and desepoxymupirocin P 16) (Schemes 1 and 2). Scheme 2. Feeding 16 to either mmpEOR/mupW or mupV strains gives PA-C 9.
Thiomarinol biosynthesis
The thiomarinol (tml) biosynthetic gene cluster was identified via complete genome sequencing of SANK73390, which was found to harbour a 97 kb plasmid consisting almost entirely of the thiomarinol biosynthetic genes. [11] These include multimodular trans-AT PKSs (tmpA, C and D), a putative FAS (tmpB) and associated tailoring and resistance genes (tmlA-Z) most of which exhibit high homology to counterparts in the mupirocin (mup) cluster ( Figure S1 ). A non-ribosomal peptide synthetase (NRPS) linked to a set of tailoring enzymes (holA-H) similar to that recently shown to control holomycin biosynthesis in Streptomyces clavuligerus is also present. [12] We have produced mutant strains of SANK73390 in which the PKS and NRPS parts of the cluster have been insertionally deactivated. Analysis of WT, NRPS and tmlU mutant strains led to the isolation of marinolic acids A 18, A6 20, and A4 21 lacking the pyrrothine (Figure 3 ). [13] Using a combination of genetic and isotopic labelling studies, we showed that the 8-hydroxyoctanoic acid side-chain is generated via successive chain extensions of a C4 precursor (4-hydroxybutyrate) derived from succinate, to give marinolic acids 18, 20 and 21 and that pyrrothine is assembled from two molecules of cysteine (HolA-D) prior to intact incorporation into thiomarinol. [13] It has recently been shown that TmlU acts as a substrate selective CoA ligase that activates marinolic acid as a thioester which in turn is the substrate for amide formation catalysed by the acyl transferase HolE. [14] Analysis of the PKS mutant revealed a series of acyl-pyrrothines designated as xenorhabdins. [13] Marinolic acid A 18 has a similar structure to PA-A 7 but lacks the epoxide and has an additional 4-hydroxyl group. The tml pathway, however has only some of the homologues of the mup genes, viz. tmlW, T, O, P, C and F, but homologues of the stand alone ACP macpE, mupU and mupV are missing. The absence of these genes from the tml cluster raises the question of how the same overall conversion can be achieved with an apparently simpler gene set. We now report results which indicate that a similar set of intermediates are indeed involved in THP ring formation and further modification in both mupirocin and thiomarinol biosynthesis. 
Chemical investigation of ΔtmlFlate stage biosynthetic steps.
Deletion of mupF (7-ketoreductase) in P. fluorescens releases a number of intermediates including mupirocin C1 14 and PA-B 8 and related shunt products in addition to mupirocin F1 15 (Scheme 1). [9b] TmlF, shows 33% amino acid sequence identity to MupF so it is likely to act as a 7-ketoreductase as does MupF in the final step in mupirocin biosynthesis, which converts mupirocin F1 15 to the dihydroxytetrahydropyran PA-A 7. Thus deletion of tmlF could release more intermediates and shunt products besides its own substrate analogous to the mupF deletion. WT SANK73390 was cultivated on a modified marine broth medium (see SI for details) which significantly improved the production of the total thiomarinols. Using this medium, a yield of 70-100 mg.L -1 TM-A 1 could be obtained, compared to 10-20 mg.L -1 in previous studies. [6] Our aim was to carry out a set of gene KOs to parallel those carried out with mupirocin, [8, 9] but reverse genetics of SANK73390 proved to be problematic. We were however successful in making the key tmlF by the method previously reported [11] using approximately 500bp arms defining an in-frame deletion from aa 10 to aa 327 in TmlF.
Analysis of extracts showed that as anticipated the production of thiomarinols A and C (1 and 2, Figure 1 ) was completely abolished, but the xenorhabdin acyl-pyrrothine metabolites were generated as normal. Further analysis of the HPLC trace indicated that various new thiomarinol-related metabolites were present albeit in minor amounts, 0.1 -1.2 mg.L -1 (Figure 4) . A major product among those minor metabolites was 8-hydroxythiomarinol C 22. Its structure, and that of other metabolites reported herein, were determined by full NMR analysis and HR-ESI-MS (see SI for details). The presence of an 8-hydroxy-THP ring as in PA-B 8 suggests that both biosynthetic pathways possess analogous pyran ring closing mechanisms, and will require similar mechanisms for removal of the 8-OH function. The only previous thiomarinol derivative reported to contain an 8hydroxyl is TM-G 6 (as a very minor metabolite of WT SANK73390), [1c] but it lacks both the 4 and 6-hydroxyls. We have not observed 6 in any of our studies, and its structure remains to be confirmed. Further detailed analysis of minor components resulted in the isolation of metabolites 23-30. These metabolites form two structurally distinct groups. The first consists of 6,7diketothiomarinol C 23, analogous to mupirocin C1 14 isolated from ∆mupC, its 4-hydroxy analogue 24, and 25 a 6,7-diketo analogue of marinolic acid A6 lacking the 4-hydroxyl and the pyrrothine. These all exist as the enol-ketone tautomers shown. The second group possesses the 6-hydroxy-7-keto THP ring (7keto-thiomarinol C 26 and its 4-hydroxy analogue 27) similar to mupirocin F1 15 isolated from ∆mupF, and products (28-30) derived from 26 and 27 by keto-enol tautomerism and/or epimerisation. This is consistent with a biosynthetic sequence to thiomarinol C 2 being similar to mupirocin after the formation of the 8-hydroxyTHP ring. Interestingly, the 4-hydroxy analogue of 8-hydroxy-thiomarinol C was not detected.
Chemical Complementation Experiments
When PA-A 7 was fed to the PKS mutant strain of SANK73390 in which all of the tailoring genes are intact, it was metabolised with both 4-hydroxylation and/or pyrrothine addition taking place to give the novel mupirocin/thiomarinol hybrid molecules 31-33 (Scheme 3). [6, 13] In this study we have investigated biotransformations of further substrates isolated from P. fluorescens and the products were isolated and fully characterised by spectroscopic methods. On feeding PA-C 9, with the mature 6,7-dihydroxypyran ring, the pyrrothine was added to give the novel metabolite 36 (MW 638) and 4-hydroxylation yielded 37 (MW 654) in similar amounts (Scheme 3). In contrast, feeding PA-B 8 or desepoxy-PA-B 17 simply led to pyrrothine addition (34 and 35, respectively) and no C-4 hydroxylated metabolites were detected. Hence it is apparent that the presence of an 8-hydroxyl inhibits 4-hydroxylation.
Desepoxy-mupirocin P 16 was also fed to cultures of the PKS mutant giving the 3 metabolites, 35, 36 and 37 all of which had the pyrrothine added. Importantly it was evident that further processing of the THP ring had occurred leading to loss of the 8hydroxyl and keto-reduction giving the fully mature 6,7dihydroxylated product 36; a minor product detected by LC-MS was the corresponding 4-hydroxylated metabolite 37. The 6,7,8trihydroxy metabolite 35 was formed via a keto-reduction and pyrrothine addition, but no loss of the 8-hydroxyl was observed. It is interesting to compare the metabolism of 8-hydroxyTHPs in P. fluorescens and Pseudoalteromonas. In the former desepoxy PA-B 17 (and PA-B 8) undergo efficient oxidation, dehydration and keto-reductions to give the bioactive 6,7-diols PA-C 9 (and PA-A 7). In contrast, in the PKS mutant of Pseudoalteromonas whilst further processing of the 6,8-dihydroxy-7-ketoTHP ring of desepoxy-mupirocin P 16 to the mature 6,7-dihydroxyTHP as well as pyrrothine addition readily occurs, feeding the 6,7,8-trihydroxy THP substrates 8 or 17, only pyrrothine addition was apparent. Scheme 3. Transformation of mupirocin analogues by the PKS mutant strain of Pseudoalteromonas SANK73390.
Conclusions
MupP has been identified as a dehydratase involved in mupirocin biosynthesis. The mupP strain of P. fluorescens was cultured and the novel 6-keto-7-alcohol, mupirocin P 13 was isolated and fully characterised. Results of chemical complementation studies feeding desepoxy-mupirocin P 16 to the mmpEOR/mupW strain blocked earlier in the biosynthetic pathway, are in accord with 16 being an intermediate in the biosynthesis of the bioactive 6,7-diol PA-C 9 (and the epoxy analogue mupirocin P 13 is deduced to be a biosynthetic precursor of PA-A 7). Hence the first step in conversion of PA-B 8 to PA-A 7 is oxidation at C-6. Furthermore feeding 16 to the mupV strain gave PA-C in accord with MupV acting before MupP. Despite some divergencies in the gene clusters, the isolation of novel metabolites including 22, 23 and 26 from cultures of the tmlF mutant of SANK73390 point to some similarities in THP ring processing in both thiomarinol and mupirocin. Indeed, feeding desepoxy-mupirocin P 16 to cultures of the PKS mutant not only led to addition of the pyrrothine but also confirmed that further processing of the THP ring occurred giving 6,7-dihydroxylated products 36 and 37. In contrast, feeding desepoxy-PA-B 17 to the PKS mutant strain simply led to addition of the pyrrothine and no THP modified products were detected. PA-B 8 is efficiently converted to PA-A 7 by mutant strains of P. fluorescens blocked earlier in the biosynthetic pathway indicating an important difference between the two pathways. Differences are evident in the two gene clusters. Homologues of the mupirocin stand-alone ACP MacpE, along with MupU and MupV are missing in SANK73390. TmpB, however, contains extra KS and ACP domains as compared to MmpB which it is speculated may replace the apparently missing activities. [13] Thus the tetrahydropyran processing reactions occurring on intermediates bound to MacpE, may take place while bound to the additional ACP on TmpB, thus obviating the need for homologues of MacpE and MupU. The lack of ring processing of PA-B 8 and desepoxy-PA-B 17 fed to the PKS mutant of Pseudoalteromonas thus may be rationalised by an inability of these substrates to be loaded onto TmpB so providing key evidence to support our proposed pathway to the marinolic acids. Structure-activity studies as well as investigations to fully understand the differences between the two pathways and to identify the genes for 4-and 6-hydroxylation in thiomarinol and 6-hydroxylation in mupirocin biosynthesis are in progress.
